Drug profile · INN
delgocitinib
ANZUPGO
delgocitinib (ANZUPGO) is a janus kinase (jak) inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — delgocitinib
- US status
- approved
- Class
- Dermatologicals (D11)
- Route
- TOPICAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
delgocitinib (ANZUPGO) is a janus kinase (jak) inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Janus Kinase (JAK) inhibitor
Primary target: Janus Kinase (JAK)
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is delgocitinib?
delgocitinib (ANZUPGO) is a janus kinase (jak) inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for delgocitinib?
ANZUPGO is a marketed brand name for delgocitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of delgocitinib?
delgocitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.